^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
GNR-084
i
Other names: GNR-084
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Generium
Drug class:
CD3 agonist, CD19 inhibitor
Related drugs:
8ms
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL (clinicaltrials.gov)
P1/2, N=36, Recruiting, AO GENERIUM | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Feb 2025
Trial completion date • Trial primary completion date
|
CD19 positive
|
GNR-084
over1year
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL (clinicaltrials.gov)
P1/2, N=36, Recruiting, AO GENERIUM | Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Dec 2023
Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CCR7 (Chemokine (C-C motif) receptor 7)
|
CD19 positive
|
GNR-084
3years
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL (clinicaltrials.gov)
P1/2, N=36, Recruiting, AO GENERIUM | Trial primary completion date: Jun 2021 --> Jun 2023
Clinical • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CCR7 (Chemokine (C-C motif) receptor 7)
|
CD19 positive
|
GNR-084
4years
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL (clinicaltrials.gov)
P1/2, N=36, Recruiting, AO GENERIUM
Clinical • New P1/2 trial
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CCR7 (Chemokine (C-C motif) receptor 7)
|
CD19 positive
|
GNR-084
Share via
